<DOC>
	<DOCNO>NCT01486433</DOCNO>
	<brief_summary>The primary objective determine effect multiple dos Epanova® ( omega fatty acid ) pharmacokinetics ( PK ) multiple 40 mg dos simvastatin .</brief_summary>
	<brief_title>The Effect Multiple Doses Epanova® Multiple-Dose Pharmacokinetics Simvastatin Healthy Normal Subjects</brief_title>
	<detailed_description>The study test hypothesis interaction Epanova concomitant administration simvastatin aspirin . No drug interaction claim , follow concomitant administration simvastatin , aspirin Epanova simvastatin aspirin , 90 % confidence interval ( CIs ) geometric mean ratio ( GMRs ) back-transformed PK parameter , area plasma concentration versus time curve ( AUC0-tau ) concentration end dose interval ( Cmax , s ) , simvastatin beta- hydroxysimvastatin acid , fall within 80 % -125 % .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Subjects must fulfil follow inclusion criterion eligible participation study , unless otherwise specify : 1 . Healthy adult male female volunteer , 1855 year age , inclusive . 2 . Body mass index ( BMI ) ≥ 18 ≤ 29.9 ( kg/m2 ) . 3 . Medically healthy clinically insignificant screen result . Hemoglobin must ≥ low limit normal . 4 . Continuous nonsmoker n't use nicotinecontaining product least 6 month prior first dose . 5 . Voluntarily consent participate study follow restriction procedure outline study . 6 . Females must nonchildbearing potential , undergone sterilization procedure least 6 month prior first dose postmenopausal amenorrhea least 2 year prior first dose follicle stimulate hormone ( FSH ) serum level ≥ 40 mIU/mL . Subjects may exclude study evidence follow criterion screen , checkin , time study , appropriate : 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal ( GI ) , endocrine , immunologic , dermatologic , neurological , psychiatric disease opinion PI . 2 . Personal familial history bleed disorder ( ) , thromboembolic disease , clinical GI bleeding , history GI surgery except uncomplicated appendectomy cholecystectomy , colorectal surgery polyp , nonmalignant tumor , diverticulum . 3 . Positive urine drug/alcohol test screen checkin . 4 . Positive result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . 5 . History presence alcoholism drug abuse within past 2 year . 6 . Subject special diet ( whatever reason ) within 28 day prior assign first dose study drug anytime study . 7 . Known sensitivity allergy soybean , fish , and/or shellfish . 8 . Hypersensitivity idiosyncratic reaction compound related simvastatin ( i.e. , HMGCoA reductase inhibitor ) and/or Epanova® and/or aspirin . 9 . Subject female pregnant lactating . 10 . Use prescription medication within 14 day prior first dose . 11 . Use overthecounter ( OTC ) medication , include herbal product ( e.g. , bromelains , danshen , dong quai [ Angelica sinensis ] , garlic , ginko biloba , ginseng , St. John 's wort , NSAIDs ) , vitamin K food supplement ( especially omega3fatty acid ) within 7 day prior first dosing . 12 . Use drug know significantly inhibit [ strong moderate ] induce liver enzymes involved drug metabolism [ CYP P450 ] ) within 30 day prior checkin . 13 . Donation blood significant blood loss within 56 day prior check . 14 . Donation plasma within 7 day prior checkin . 15 . Participation another clinical trial within 30 day prior checkin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>eicosapentaenoic acid</keyword>
	<keyword>docosapentaenoic acid</keyword>
	<keyword>arachidonic acid</keyword>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>simvastatin</keyword>
</DOC>